The Leukemia & Lymphoma Society and Epizyme Partner to Develop Personalized Therapeutic for Genetically-Defined Mixed Lineage Leukemia (MLL) Patients

WHITE PLAINS, N.Y. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Leukemia & Lymphoma Society (LLS) and Epizyme announced today that they will jointly support pre-clinical and Phase 1 development of Epizyme’s DOT1L-targeted histone methyltransferase inhibitor (HMTi) for Mixed Lineage Leukemia (MLL), a devastating acute leukemia that affects both pediatric and adult patients. LLS has committed to provide up to $7.5 million in milestone-based funding to Epizyme to support the program through Phase 1. Epizyme is creating personalized therapeutics for genetically-defined oncology and rare disease patients, with a focus on small molecule inhibitors of histone methyltransferases, an important epigenetic target class.